Table 3.
Ultimate Outcomes Following Spontaneous and Precipitated Acute Urinary Retention (AUR) Episodes Stratified by Finasteride Versus Placebo Treatment Groups
| Risk Reduction | ||||
|---|---|---|---|---|
| Finasteride n (%) | Placebo n (%) | P value | with Finasteride | |
| Spontaneous AUR | 20 | 52 | <.001 | 62% |
| Subsequent spontaneous AUR | 3 (15) | 8(15) | .999 | |
| Subsequent precipitated AUR | 1 (5) | 1(2) | .481 | |
| Any subsequent AUR | 4(20) | 9(17) | .746 | |
| Subsequent BPH-related surgery | 8 (40) | 39 (75) | .011 | |
| Precipitated AUR | 22 | 47 | <.001 | 52% |
| Subsequent spontaneous AUR | 0 | 4(9) | .299 | |
| Subsequent precipitated AUR | 3 (14) | 6(13) | .999 | |
| Any subsequent AUR | 3(14) | 10 (21) | .528 | |
| Subsequent BPH-related surgery | 3 (14) | 12 (26) | .355 |
AUR, acute urinary retention; BPH, benign prostatic hyperplasia.